The estimated Net Worth of John E Elicker is at least 7.74 百万$ dollars as of 10 March 2020. Mr. Elicker owns over 18,407 units of Bristol-Myers Squibb Co stock worth over 3,649,158$ and over the last 12 years he sold BMY stock worth over 4,089,253$. In addition, he makes 0$ as Executive Vice President of Investor Relations at Bristol-Myers Squibb Co.
Sign up
Mr. Elicker BMY stock SEC Form 4 insiders trading
John has made over 33 trades of the Bristol-Myers Squibb Co stock since 2012, according to the Form 4 filled with the SEC. Most recently he exercised 18,407 units of BMY stock worth 894,396$ on 10 March 2020.
The largest trade he's ever made was exercising 33,715 units of Bristol-Myers Squibb Co stock on 5 June 2013 worth over 687,449$. On average, John trades about 7,534 units every 75 days since 2012. As of 10 March 2020 he still owns at least 75,101 units of Bristol-Myers Squibb Co stock.
You can see the complete history of Mr. Elicker stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
John Elicker biography
John E. Elicker serves as Executive Vice President of Investor Relations of the Company. 2012 to 2017 – Senior Vice President, Public Affairs and Investor Relations 2017 to 2019 – Senior Vice President, Corporate Affairs and Investor Relations 2019 to present – Executive Vice President, Investor Relations
How old is John Elicker?
John Elicker is 60, he's been the Executive Vice President of Investor Relations of Bristol-Myers Squibb Co since 2020. There are 10 older and 25 younger executives at Bristol-Myers Squibb Co. The oldest executive at Bristol-Myers Squibb Co. is Vicki Sato, 71, who is the Lead Independent Director.
What's John Elicker's mailing address?
John's mailing address filed with the SEC is BRISTOL-MYERS SQUIBB COMPANY, 430 E. 29TH STREET, 14 FLOOR, NEW YORK, NY, 10016.
Insiders trading at Bristol-Myers Squibb Co
Over the last 16 years, insiders at Bristol-Myers Squibb Co have traded over 318,151,721$ worth of Bristol-Myers Squibb Co stock and bought 211,503 units worth 6,601,565$ . The most active insiders traders include Lamberto Andreotti、James M Cornelius、Giovanni Caforio. On average, Bristol-Myers Squibb Co executives and independent directors trade stock every 8 days with the average trade being worth of 1,682,720$. The most recent stock trade was executed by Cari Gallman on 1 August 2024, trading 1,061 units of BMY stock currently worth 51,554$.
What does Bristol-Myers Squibb Co do?
The Bristol-Myers Squibb Company is an American multinational pharmaceutical company. Headquartered in New York City, BMS is one of the worlds largest pharmaceutical companies and consistently ranks on the Fortune 500 list of the largest U.S. corporations. For fiscal 2022, it had a total revenue of $46.2 billion.
What does Bristol-Myers Squibb Co's logo look like?
Complete history of Mr. Elicker stock trades at Bristol-Myers Squibb Co
Bristol-Myers Squibb Co executives and stock owners
Bristol-Myers Squibb Co executives and other stock owners filed with the SEC include:
-
Giovanni Caforio,
Chairman of the Board, Chief Executive Officer -
Sandra Leung,
Executive Vice President, General Counsel -
Dr. Giovanni Caforio M.D.,
Chairman & CEO -
Christopher Boerner,
Executive Vice President and Chief Commercial Officer -
David Elkins,
Executive Vice President and Chief Financial Officer Member of the Leadership Team -
Rupert Vessey,
Executive Vice President, Research and Early Development Member of the Leadership Team -
Louis Schmukler,
Executive Vice President, President - Global Product Development and Supply -
David V. Elkins,
Exec. VP & CFO -
Rupert Vessey BCH, BM, DPHIL, M.A.,
Exec. VP and Pres of Research & Early Devel. -
Sandra Leung Esq.,
Exec. VP & Gen. Counsel -
Dr. Christopher S. Boerner,
Exec. VP & Chief Commercialization Officer -
Vicki Sato,
Lead Independent Director -
Matthew Emmens,
Independent Director -
Peter Arduini,
Independent Director -
Dinesh Paliwal,
Independent Director -
Theodore Samuels,
Independent Director -
Karen Vousden,
Independent Director -
Robert Bertolini,
Independent Director -
Gerald Storch,
Independent Director -
Phyllis Yale,
Independent Director -
Julia Haller,
Independent Director -
Michael Bonney,
Independent Director -
Derica Rice,
Independent Director -
Paula Price,
Independent Director -
Tim Power,
Vice President of Investor Relations -
Joseph Eid,
Senior Vice President and Head of Global Medical Affairs Member of the Leadership Team -
Karen Santiago,
Senior Vice President, Corporate Controller -
Adam Dubow,
Senior Vice President, Chief Compliance Officer and Ethics Officer -
Paul von Autenried,
Chief Information Officer, Senior Vice President -
Elizabeth Mily,
Executive Vice President - Strategy & Business Development -
Kathryn Metcalfe,
Executive Vice President - Corporate Affairs Member of the Leadership Team -
Samit Hirawat,
Executive Vice President, Chief Medical Officer, Global Drug Development Member of the Leadership Team -
Nadim Ahmed,
Executive Vice President and President - Hematology -
John Elicker,
Executive Vice President of Investor Relations -
Ann Judge,
Chief Human Resource Officer, Senior Vice President Member of the Leadership Team -
Ann M. Powell Judge,
Exec. VP & Chief HR Officer -
Adam Dubow,
Sr. VP, Chief Compliance & Ethics Officer -
Timothy Power,
VP & Head of Investor Relations -
Paul von Autenried,
Exec. VP & Chief Information Officer -
Greg Meyers,
Exec. VP and Chief Digital & Technology Officer -
Jose Baselga,
Director -
Alan J Lacy,
Director -
Joseph C Caldarella,
VP & Financial Controller -
Anne Nielsen,
Chief Compliance & Ethics Off -
Laurie H M.D. Glimcher,
Director -
Michael Grobstein,
Director -
Togo D Jr West,
Director -
Emmanuel Blin,
SVP, Head of Commercialization -
Francis M Cuss,
SVP Dscvry & Exp Clinl Resrch -
Murdo Gordon,
SVP, Head of Worldwide Markets -
Thomas J. Jr. Lynch,
Director -
Karin Shanahan,
EVP, Glob. Prod. Dev. & Supply -
Lynelle Hoch,
President, Cell Therapy Org. -
Phil M Holzer,
SVP and Controller -
Ahn Amanda Poole,
EVP, Chief Human Resources -
Samuel J Moed,
SVP, Strat Plan & Analysis -
Michelle Weese,
EVP, Corporate Affairs -
Paul Biondi,
SVP, Head of Strategy & BD -
Charles A Bancroft,
EVP, Head of Integration -
Ann Powell,
EVP, Chief Human Resources -
Frances K Heller,
SVP, Business Development -
Brian Daniels,
SVP Global Development -
Elliot Sigal,
EVP, CSO & President R&D -
Beatrice J Cazala,
SVP Comm Ops & Pres GC Euro EM -
Robert T Zito,
SVP & Chief Comm Officer -
Jeremy M Levin,
SVP Strat Transactions -
R Sanders Williams,
Director -
Anthony C Hooper,
President US Pharmaceuticals -
Louis J Freeh,
Director -
Anthony A Mcbride,
SVP Human Resources -
De Notaristefani Carlo,
President, Tech Ops -
Leif Johansson,
Director -
John E Celentano,
SVP Strat & Productivity Trans -
Jean Marc Huet,
SVP & CFO -
James M Cornelius,
Chairman & CEO -
Lewis B Campbell,
Director -
Medina Manuel Hidalgo,
Director -
Benjamin Hickey,
President, RayzeBio Org. -
Gregory Scott Meyers,
EVP, Chief Digital & Tech Off. -
Sharon Greenlees,
SVP & Controller -
Deepak Bhatt,
Director -
Michael R. Mc Mullen,
Director -
Adam Lenkowsky,
EVP, Chief Commercial Officer -
Robert M Plenge,
EVP, Chief Research Officer -
Cari Gallman,
EVP, Corporate Affairs